Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did you notice when Eric said "we've partnered with Pharmaceutical companies?" Little nugget that our secret CMO downstream purification partner is in fact a pharmaceutical company!
OK Tom! Spend all day going to all the boards saying that stupid statement! Lol. Anyone that has done a lick of DD is totally laughing. A month after getting funding from the Government. Biosynthesis scale up in progress, months away from Clinical trials! Michael Woudenberg left a Huge company like Phyton Biotech with over 20 years experience to join the InMed sinking ship!! ?? ok dude!!! Makes sense! Oh yes, the company has 24 million in the bank and they're sinking!! ??
No worries! These guys in this industry get bored all the time and move on to new projects! Everything is in place for InMed now! The heavy lifting is all done! It's all about execution at this point! Also things are moving forward. 750 will definitely be in clinics 2H this year. InMed has multiple partnerships. The Downstream partner hopefully will be named soon. I know it seems small but the funding InMed got from the Government wasn't just given to them. There was a lot of competition for that money. The Canadian Government did a lot of DD before handing that money over, they expect InMed to be very successful! I'm as excited now as I have ever been, if not more!
Did anyone get any clue today about our secret CMO downstream partner that might be announced? Eric's one statement about " hope to understand process of Biosynthesis by end of the year!" I totally think he's talking about the scale up process and commercializing it. But I don't think we're getting that announcement soon. Overall I was very encouraged by the presentation. Everything is still a go on the timeline. No setbacks. Plus inMed might dabble in the recreational market! He said once again, 2019 will be a Transformational year for the company! I love that line!
(CMO) Contract Manufacturing organization.
Nice run we have going but would be nice to get some news so this run can be sustainable!
I agree, I wasn't happy that insiders sold back last January. I like to give them the benefit of the doubt. Pre clinical, no revenue. They needed some money. That said, 2019 is a put up or shut up year for Inmed. They have a lot of big goals and milestones to hit. If they don't, I will be joining you!
I saw an interview with Cronos exec where he stated they are still a couple years from producing any Cannabinoids. InMed is already there. Downstream CMO TBA soon. If I can find the interview I will post it.
Might as well celebrate a green day with markets settling down. US$0.25 and C$0.34 with moderate volume.
One thing to take into the New Year is that all of the successes that are baked into the share price are gone.
Normally, the share price reflects lots of promises expected to be achieved and as a result, new announcements reinforce the current price and only a new promise pushes things up.
The current share price reflects the whole market ignoring potential and holding cash. Soon this money will return and the expectations on success will start to push the share price up as promises are accepted as realistic again. Currently, our Market Cap is C$58 million which is barely three times the cash in the bank. As Tom Tinne mentioned earlier today, we are back where we started.
However, we have come further down the road and we have new promises on the way. Here is a short list of potential value drivers in over the next 30 days:
1. Obviously, the unnamed CMO partner - This is not factored in and I don't think it ever was. No prediction on the lift but if our 'lil partner turns out to be a name brand company ...
2. Glaucoma partner - we know that this is not the focus of the current investors and it is a latent asset. A partnership deal with a valuation of $20-60m could give us a $1 on the share price. But we have to note that it is worth zero if there is no partner. So current value per share could be C$0.01 - 0.05 today.
3. Pain - far too early in the pipeline to give it a value today but this is also a partnering strategy. Partnership deals can come out of the woodwork very quickly or not at all. I think today this could be C$0.01 to 0.03 but like above, an early partnership could put C$0.50 on the share price.
4. INM-750 - there some value recorded here but without permission to go to the clinic, it will be undervalued. Just getting permission in the form of an IND filing, will give the share price a big boost. The the next big boost will be at Phase II trials I suspect as early as first half of 2020. Today the value is probably C$0.10 - 0.15. Traditionally, clinical phase biotechs can have a valuation of C$200m - 500m. That should add C$1 in the first half of 2019 and possibly C$2 - 3 if this gets broad exposure in the USA as helping kids with EB
5. Biosynthesis - is a short route to profit. There is a huge potential for the research-use-only market as well as a therapeutics market. Big pharma likes a predictable supply chain and preferably one they can control from end to end. CBD from farms in the Congo could be really cheap but hardly a predictable, stable and with guaranteed quality. The licensing value from biosynthesis alone is a huge potential. It is obvious from the change in focus that the last round of investors are here for biosynthesis. This represents close to C$0.60 of our current C$0.34 valuation ... that's about 190% of where we are today. With a bit of marketing or an announcement of our 'lil CMO, could drag us back to the old valuation right away and with a potential multiplier.
6. Patents - More patents on the different Cannabinoids to further lock down access to the minor cannabinoids and widen the moat. Further preclinical research accessing other minor cannabinoids from biosynthesis becomes the oyster no one else has access to is a very nice place to be.
7. Socially Responsible Big Pharma - We need to feed the world - bet you didn't think about this one - similarly when biofuels started to replace food crop production a decade ago, there was a big push back. Prices of veggies in Canada are expected to rise as greenhouses are converted from tomatoes to cannabis. This will push governments to ensure that cultivation licenses are limited and feeding people will come first. Big Pharma will need to demonstrate social responsibility and not acquire products at the expense of food cultivation. There is only one way to provide cannabinoids without replacing food production. Biosynthesis is the only socially responsible answer.
8. Revenues - we are literally staring at commercial scale revenue in 2019. Like I can't can't begin to tell you how much that tickles the testicles. Not just revenue, but predictable revenue that can grow rapidly regardless of the price of CBD and THC. We are looking at producing stuff that no one else can. We will be first to market and can lock down long-term contracts with guaranteed production numbers. Both Big Pharma and investors like predictability ... A LOT!
Lots of things to drive both short term and long term value!
#STMF
Also almost two months ago we appointed Michael Woudenberg as Vice president, CMC! Now why would Michael Woudenberg leave a HUGE successful company like Phyton Biotech where he has an awesome job to join a scam company like InMed that won't produce anything for years? Or join InMed that will be Bankrupt in the next year or so! Maybe he did because InMed has the golden egg! Plus their technology is disruptive and game changing? Hmm, I'll go with the latter! Read between the lines!
What results? I haven't heard of any company Biosynthesizing any of the rare Cannabinoids on a commercial scale! Yes other companies are selling their souls and future profits for different partnerships so they can get huge funding now. InMed doesn't have to do that. They are dang smack in the middle of upscaling Biosynthesis! No other company can do it using Ecoli! Yeast is only good for making beer and bread! Not making Cannabinoids identical to nature! Plus InMed has updated us on all their progress and goals during the last CC! Only about 5 to 6 weeks ago. I have no doubt when they're good and ready, they'll put out a PR that will blow these other partnership news out of the water! Yes, Downstream CMO partner! It's coming!
2019 should be filled with big news for us! I always go back to 8cap investing 15 million dollars in InMed and the Government just handing over 500k. I know that doesn't sound like a lot but even if you had the money would you just hand over half a million dollars? I know I wouldn't. Plus I always think of the Forbes article. It's an old article but a very good one. The peer reviewed journal! What about Michael Woudenberg? He just recently left a very successful position to join Inmed! Do you think he would do that if InMed wasn't going anywhere? I think he did it because he knows this technology will be huge and a gamechanger! Sometimes I have to read between the lines to keep confidence. It is hard right now because the long period of time without a word from the company and the dropping SP. I really feel 2019 will be a much better year and only the beginning! IMHO!
Thank you my friend! You have a great New year your self. We have a lot to look forward too!
I really believe that InMed will take a huge step forward in 2019! It seems like it's lining up that way! Could be wishful thinking but I don't think so.
Happy Holidays to you and yours also Matilda1!
Buying a bunch more today! These prices don't look good in our account right now now but definitely a Christmas treat when you're buying. Merry Christmas everyone!
Oldie But Goodie!
That's not like you! I don't think it will go that low, that's lower than money in the bank! Still believe 2019 will be big, if not! I'll scrape what's left and get out myself!
Todd Harrison, CB1Cap has a large position with InMed! They must not share your opinion!
Totally agree GW!
I forgot! INM-750 is just months away from entering Human Trials and we should be hearing about patent approval any time now! Inmed isn't leaving the station!!
Ya there is another company in the middle of scaling up Biosynthesis to reproduce all 90+ cannabinoids exactly what's found in nature! Using e coli which is the same to make insulin! You're right, Inmed is never leaving the station! I guess 8cap bank are a bunch of idiots just giving inmed 15 million for no reason. The Government just wanted to throw away 500k! A bunch of stupid scientists at the University of British Columbia don't know what the heck they're doing! You're right! This leadership team with decades and decades of experience came to inmed to fail! Such a joke!! Lol.
Thanks Sam! Makes sense.
I don't really get how the Farm bill affects InMed?
Who cares unless you're a day trader. Not worried. Let's see where we are this time next year!
Hopefully this works HB!
https://www.pressreader.com/usa/readers-digest/20190101/281900184184135
The market has gotten wind of it! Inmed has to prove it to the market! Hopefully 1st half of 2019!
That's fair enough! Thanks for the explanation. Hopefully 2019 will be a much better year for hitting goals and generating some revenues!
I have a question for Portfoliomaster. What did InMed do to change your opinion from this company being garbage to saying BUY BUY BUY before it's to late? You've been saying it for a few months now even though the SP has still been struggling? Thanks.
That could happen with EB alone but that's further down the road. Very very possible with Biosynthesis by 2020.
I added 3k shares today, I feel the same way. I think there is something big coming from the unnamed downstream partner! IMO, I think it's a big pharma company that might be doing more than helping with the downstream purification process! Maybe just checking out what this Biosynthesis technology is all about and how disruptive it can be? Might be InMed's first and really huge licensing contract? Maybe globally? I'm just spitballing but I might not be that far off! Do you know why inMed has so many bashers? Because now they have financing for the next couple years, they're doing not talking! They're not putting out bullshiz PR's every other day! Their recent hire of Michael Woudenberg is huge! That's very telling. 2019 should be a gigantic year for InMed and it's investors! GLTA!!
Les, I wasn't asking for you to take it down. I was just wondering if you guys can change them anytime you want.
Eric Adams! I get lazy sometimes! Lol.
The only prediction I've heard him give is $20 by February 2020! I can possibly see that happening between Biosynthesis and Clinics for 750! Plus a very good chance InMed will have partner to move 085 ahead by then. I definitely think it's possible!
GW, How long do moderators need to keep a sticky up? The one Les has up is from 2016? Can he just replace that one if there was a post he'd love to put up?